Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)
Ratios

Rocket Pharmaceuticals (RCKT) Accumulated Depreciation & Amortization (2016 - 2025)

Rocket Pharmaceuticals' Accumulated Depreciation & Amortization history spans 10 years, with the latest figure at $8.9 million for Q4 2025.

  • For Q4 2025, Accumulated Depreciation & Amortization rose 23.61% year-over-year to $8.9 million; the TTM value through Dec 2025 reached $8.9 million, up 23.61%, while the annual FY2025 figure was $8.9 million, 23.61% up from the prior year.
  • Accumulated Depreciation & Amortization for Q4 2025 was $8.9 million at Rocket Pharmaceuticals, up from $7.2 million in the prior quarter.
  • Across five years, Accumulated Depreciation & Amortization topped out at $8.9 million in Q4 2025 and bottomed at $1.1 million in Q1 2023.
  • The 5-year median for Accumulated Depreciation & Amortization is $3.5 million (2023), against an average of $4.1 million.
  • The largest annual shift saw Accumulated Depreciation & Amortization plummeted 81.62% in 2023 before it soared 278.95% in 2025.
  • A 5-year view of Accumulated Depreciation & Amortization shows it stood at $3.2 million in 2021, then increased by 21.88% to $3.9 million in 2022, then grew by 25.64% to $4.9 million in 2023, then soared by 46.94% to $7.2 million in 2024, then rose by 23.61% to $8.9 million in 2025.
  • Per Business Quant, the three most recent readings for RCKT's Accumulated Depreciation & Amortization are $8.9 million (Q4 2025), $7.2 million (Q3 2025), and $4.5 million (Q2 2025).